Starpharma signs DEP Research Agreement with US Biopharma Co

On 7 December 2021 Starpharma reported that it has signed an exploratory DEP Research Agreement with Genentech, a member of the Roche Group, with an initial focus on evaluating DEP (dendrimer based) drug conjugates (Press release, Starpharma, DEC 7, 2021, View Source [SID1234634709]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Starpharma also has a number of existing DEP partnerships with leading international pharmaceutical companies, including AstraZeneca, Merck & Co., Inc., Chase Sun, as well as several undisclosed partnerships.

Starpharma’s DEP technology has already yielded four clinical stage products.

About DEP
Starpharma’s proprietary dendrimer-based DEP platform has broad commercial applicability in drug delivery by enhancing the therapeutic utility of drugs through improved solubility, efficacy and pharmacokinetic control, reductions in certain toxicities (e.g., bone marrow toxicity) and creating a unique intellectual property position. The novel DEP platform has shown reproducible advantages across a wide range of drug classes and can be utilised with both small molecule drugs, peptides and proteins, and in the development of unique DEP based ADCs, radiotherapies and radiodiagnostics.

Potential benefits of DEP dendrimer drug delivery include:
• Improving efficacy
• Improving therapeutic index
• Reducing toxic side effects of drugs
• Enhanced and controllable pharmacokinetics
• Tumour targeting
• Increased aqueous solubility, avoiding the need for toxic excipients (e.g., polysorbate-80) thus reducing the need for steroid pre-treatment
• Delivering a variety of payloads (small molecules, proteins, radio-isotopes)
• Creation of new intellectual property

Starpharma has three phase 2 clinical stage DEP assets, multiple preclinical DEP programs, and has applied its DEP technology in partnership with pharmaceutical companies for many different applications (passive and targeted ADC and radiotheranostics) and diseases (oncology and nononcology applications).